Esperion Therapeutics (ESPR) Proxy filing summary

Executive summary

• Entered into a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, plus contingent milestone payments up to $100 million based on future net sales performance.

• Transaction expected to close in the third quarter of 2026, with the company operating independently until then.

• ARCHIMED, a healthcare-focused investment firm, will serve as a strategic and financial partner post-acquisition.

• Forward-looking statements highlight risks and uncertainties, including regulatory approvals, shareholder approval, and potential disruption to business operations.

Voting matters and shareholder proposals

• A special meeting of stockholders will be convened to vote on the proposed acquisition and related matters.

• Proxy statement and related materials will be filed with the SEC and made available to securityholders.

Board of directors and corporate governance

• Directors and executive officers may be deemed participants in the proxy solicitation for the acquisition.

• Information on directors’ and officers’ interests in the transaction will be disclosed in the proxy statement.